Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan


  • Efrain Antonio GonzalezEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_9268

Generic Name


Brand Name



Central Monoamine-Depleting Agents

Proposed Mechanism(s) of Action

Reversible inhibition of vesicular monoamine transporter 2 (VMAT2), which is a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release from the presynaptic cell.


Treatment of tardive dyskinesia in adults.

Off Label Use


Side Effects


Akathisia, balance disorders/fall, prolonged QT syndrome, especially if co-administered with strong CYP2D6 or CYP3A4 inhibitors, or with patients who are poor CYP2D6 metabolizers.


Anticholinergic effects, headache, vomiting, nausea, arthralgia, somnolence.

References and Readings

  1. Bari, M., Shiwach, R., Jimenez, R., Siegert, S., & O’Brien, C. (2016). Open-label extension of KINECT: A phase 2 study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27. 001). Neurology, 86(16 Supplement), S27–001.Google Scholar
  2. Free Drug Online and PDA Software. www.epocrates.com
  3. Free Drug Online and PDA Software. www.medscape.com
  4. General Information. www.medscape.com
  5. Hauser, R. A., Factor, S. A., Marder, S. R., Knesevich, M. A., Ramirez, P. M., Jimenez, R., …, O’Brien, C. F. (2017). KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry, 174(5), 476–484.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of PsychologyNova Southeastern UniversityFort LauderdaleUSA
  2. 2.Utah State UniversityLoganUSA